Preparation, characterization, cellular uptake and evaluation in vivo of solid lipid nanoparticles loaded with cucurbitacin B

Drug Development and Industrial Pharmacy

Volumn 39, Issue 5, 2013, Pages 770-779

  Hu, Haiyang ^a   Liu, Dan ^b   Zhao, Xiuli ^a   Qiao, Mingxi ^a   Chen, Dawei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Anti tumor efficacy; Cellular uptake; Cucurbitacin B; Cytotoxicity; Solid lipid nanoparticles; Tissues distribution

Indexed keywords

ANTINEOPLASTIC AGENT; CUCURBITACIN; CUCURBITACIN B; PHOSPHATIDYLCHOLINE; POLOXAMER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG ANALYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; DRUG TRANSPORT; ENCAPSULATION; HEART; IC 50; IN VIVO STUDY; INTERNALIZATION; KIDNEY; LIVER; LUNG; MORPHOLOGY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; SPLEEN; TISSUE DISTRIBUTION; TUMOR GROWTH; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DRUG CARRIERS; HEP G2 CELLS; HUMANS; LIPIDS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; TRITERPENES;

EID: 84875911854     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.702348     Document Type: Article

References (51)

1. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. (2005). Cucurbitacins and cucurbitane glycosides: Structures and biological activities. Nat Prod Rep, 22:386-399.
2. Peters RR, Saleh TF, Lora M, Patry C, de Brum-Fernandes AJ, Farias MR et al. (1999). Anti-inflammatory effects of the products from Wilbrandia ebracteata on carrageenan-induced pleurisy in mice. Life Sci, 64:2429-2437.
3. Yesilada E, Tanaka S, Sezik E, Tabata M. (1988). Isolation of an antiinflammatory principle from the fruit juice of Ecballium elaterium. J Nat Prod, 51:504-508.
4. Agil A, Miro M, Jimenez J, Aneiros J, Caracuel MD, Garcia-Granados A et al. (1999). Isolation of ani-hepatotoxic principle form the juice of Ecballium elaterium. Planta Med, 65:673-675.
5. Oh H, Mun YJ, Im SJ, Lee SY, Song HJ, Lee HS et al. (2002). Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med, 68:832-833.
6. Ukiya M, Akihisa T, Yasukawa K, Tokuda H, Toriumi M, Koike K et al. (2002). Anti-inflammatory and anti-tumor-promoting effects of cucurbitane glycosides from the roots of Bryonia dioica. J Nat Prod, 65:179-183.
7. Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M. (2007). Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol, 73:56-67.
8. Bartalis J, Halaweish FT. (2005). Relationship between cucurbitacins reversed-phase high-performance liquid chromatography hydrophobicity index and basal cytotoxicity on HepG2 cells. J Chromatogr B Analyt Technol Biomed Life Sci, 818:159-166.
9. Marengo E, Cavalli R, Caputo O, Rodriguez L, Gasco MR. (2000). Scale-up of the preparation process of solid lipid nanospheres. Part I. Int J Pharm, 205:3-13.
10. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161-177.
11. Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev, 53:283-318.
12. Maeda H. (2001). SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev, 46:169-185.
13. Muggia FM. (1999). Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res, 5:7-8.
14. Maeda H, Matsumura Y. (1989). Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst, 6:193-210.
15. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MN. (2009). PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res, 26:2495-2503.
16. Wang JX, Sun X, Zhang ZR. (2002). Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm, 54:285-290.
17. Weyenberg W, Filev P, Van den Plas D, Vandervoort J, De Smet K, Sollie P et al. (2007). Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm, 337:291-298.
18. Labouret A, Thioune O, Fessi H, Devissaguet JP, Puisieux F. (1995). Application of an original process for obtaining colloidal dispersions of some coats polymers. Preparation, characterization, industrial scaling up. Drug Dev Ind Pharm, 21:229-241.
19. Torchilin VP. (2010). Passive and active drug targeting: Drug delivery to tumors as an example. Handb Exp Pharmacol, 197:3-53.
20. Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M. (1998). Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res, 15:128-132.
21. Schwarz C, Mehnert W, Lucks JS, Muller RH. (1994). Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release, 30:83-96.
22. Kedmi R, Ben-Arie N, Peer D. (2010). The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 31:6867-6875.
23. Lockman PR, Koziara JM, Mumper RJ, Allen DD. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target, 12:635-641.
24. Schafer-Korting M, Mehnert W, Korting HC. (2007). Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev, 59:427-443.
25. Bartalis J, Halaweish FT. (2011). In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines. Bioorg Med Chem, 19:2757-2766.
26. Lee MK, Choi L, Kim MH, Kim CK. (1999). Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. Int J Pharm, 191:87-93.
27. Park KM, Lee MK, Hwang KJ, Kim CK. (1999). Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int J Pharm, 183:145-154.
28. Hurrell S, Cameron RE. (2003). The effect of buffer concentration, pH and buffer ions on the degradation and drug release from polyglycolide. Polym Int, 52:358-366.
29. Liu J, Zhu J, Du Z, Qin B. (2005). Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles. Drug Dev Ind Pharm, 31:551-556.
30. Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257-1272.
31. Meng W, Parker TL, Kallinteri P, Walker DA, Higgins S, Hutcheon GA et al. (2006). Uptake and metabolism of novel biodegradable poly (glycerol-adipate) nanoparticles in DAOY monolayer. J Control Release, 116:314-321.
32. Jensen KD, Nori A, Tijerina M, Kopeckova P, Kopecek J. (2003). Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release, 87:89-105.
33. Panyam J, Labhasetwar V. (2003). Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res, 20:212-220.
34. Chavanpatil MD, Khdair A, Panyam J. (2006). Nanoparticles for cellular drug delivery: Mechanisms and factors influencing delivery. J Nanosci Nanotechnol, 6:2651-2663.
35. Park K, Kim JH, Nam YS, Lee S, Nam HY, Kim K et al. (2007). Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release, 122:305-314.
36. Hu Y, Xie J, Tong YW, Wang CH. (2007). Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release, 118:7-17.
37. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release, 82:105-114.
38. Tranchant T, Besson P, Hoinard C, Delarue J, Antoine JM, Couet C et al. (1997). Mechanisms and kinetics of alpha-linolenic acid uptake in Caco-2 clone TC7. Biochim Biophys Acta, 1345:151-161.
39. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm, 348:137-145.
40. Nassimi M, Schleh C, Lauenstein HD, Hussein R, Hoymann HG, Koch W et al. (2010). A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm, 75:107-116.
41. Silva AC, Gonzalez-Mira E, Garcia ML, Egea MA, Fonseca J, Silva R et al. (2011). Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces, 86:158-165.
42. Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 107:215-228.
43. Jiang W, Kim BY, Rutka JT, Chan WC. (2008). Nanoparticlemediated cellular response is size-dependent. Nat Nanotechnol, 3:145-150.
44. Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev, 16:195-214.
45. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H et al. (2009). Targeting of tumor endothelium by RGDgrafted PLGA-nanoparticles loaded with paclitaxel. J Control Release, 140:166-173.
46. Vicent MJ, Duncan R. (2006). Polymer conjugates: Nanosized medicines for treating cancer. Trends Biotechnol, 24:39-47.
47. Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41:189-207.
48. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release, 65:271-284.
49. Gaumet M, Vargas A, Gurny R, Delie F. (2008). Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm, 69:1-9.
50. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res, 19:1137-1143.
51. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 59:299-307.